Literature DB >> 8400327

Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer.

W R Miller1, D M Watson, W Jack, U Chetty, R A Elton.   

Abstract

In two separate cohorts of breast cancer patients presenting without evidence of distant metastatic disease, high levels of tumour cyclic AMP binding proteins (> 8 pmol/mg cytosol protein) have been shown to be associated with poor prognosis in terms of both disease recurrence and overall survival. This association is independent of known established prognostic factors and allows the identification of a small subgroup of patients whose outlook warrants the implementation of aggressive systemic therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400327     DOI: 10.1007/bf00682703

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Inverse relation between estrogen receptors and cyclic adenosine 3':5'-monophosphate-binding proteins in hormone-dependent mammary tumor regression due to dibutyryl cyclic adenosine 3':5'-monophosphate treatment or ovariectomy.

Authors:  J S Bodwin; T Clair; Y S Cho-Chung
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

Review 3.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.

Authors:  Y S Cho-Chung
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

4.  A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues.

Authors:  R A Hawkins; A Hill; B Freedman
Journal:  Clin Chim Acta       Date:  1975-10-15       Impact factor: 3.786

Review 5.  Role of site-selective cAMP analogs in the control and reversal of malignancy.

Authors:  Y S Cho-Chung; T Clair; G Tortora; H Yokozaki
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

6.  Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity.

Authors:  W R Miller; J Telford; J M Dixon; R A Hawkins
Journal:  Eur J Cancer Clin Oncol       Date:  1985-04

7.  Cyclic adenosine 3':5-monophosphate receptor proteins in hormone-dependent and -independent rat mammary tumors.

Authors:  Y S Cho-Chung; T Clair; M Schwimmer; L Steinberg; J Rego; F Grantham
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

8.  Cyclic AMP binding proteins and prognosis in breast cancer.

Authors:  W R Miller; R A Elton; J M Dixon; U Chetty; D M Watson
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

9.  Cyclic AMP binding proteins in human breast cancer.

Authors:  W R Miller; R O Senbanjo; J Telford; D M Watson
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

  10 in total
  12 in total

1.  Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

Authors:  H Wang; Q Cai; X Zeng; D Yu; S Agrawal; R Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  ABC of breast diseases. Prognostic factors.

Authors:  W R Miller; I O Ellis; J R Sainsbury; J M Dixon
Journal:  BMJ       Date:  1994-12-10

3.  Antisense DNAs as multisite genomic modulators identified by DNA microarray.

Authors:  Y S Cho; M K Kim; C Cheadle; C Neary; K G Becker; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

4.  Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

Authors:  G Tortora; R Caputo; V Damiano; R Bianco; S Pepe; A R Bianco; Z Jiang; S Agrawal; F Ciardiello
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

5.  Regulation of the functional interaction between cyclin D1 and the estrogen receptor.

Authors:  J Lamb; M H Ladha; C McMahon; R L Sutherland; M E Ewen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.

Authors:  Watcharin Loilome; Sasithorn Yooyuen; Nisana Namwat; Paiboon Sithithaworn; Anucha Puapairoj; Junko Kano; Masayuki Noguchi; Masanao Miwa; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2012-08-26

7.  Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.

Authors:  Hasaya Dokduang; Sirinun Juntana; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Narong Khuntikeo; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-06-29

Review 8.  Transcriptional regulation of multidrug resistance in breast cancer.

Authors:  R I Glazer; C Rohlff
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Analysis of cAMP RI alpha mRNA expression in breast cancer: evaluation of quantitative polymerase chain reaction for routine use.

Authors:  J M Bartlett; M J Hulme; W R Miller
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

10.  Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.

Authors:  T Troiani; L Vecchione; E Martinelli; A Capasso; S Costantino; L P Ciuffreda; F Morgillo; D Vitagliano; E D'Aiuto; R De Palma; S Tejpar; E Van Cutsem; M De Lorenzi; M Caraglia; L Berrino; F Ciardiello
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.